Wockhardt’s breakthrough respiratory drug Zaynich moves a step closer to market as the US FDA accepts it for review, boosting approval odds and keeping the company on track for its mid-2026 launch target. Equity analyst Vishal Manchanda says the priority review points to a likely early-FY27 approval, even as markets react sharply and other India-focused pipeline drugs await clarity.

Read more